INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) announced on September 30, 2026, that CelSiege Biosciences Inc. has appointed it, on a non-exclusive basis, as its authorized introduction and business development representative in Japan and the People’s Republic of China for IN01, a clinical-stage cancer immunotherapy program. The appointment, made under a Letter of Authorisation signed on September 18, 2026, by Johan Indot, Founder and Director of CelSiege, allows BIOT to introduce the IN01 Program to prospective strategic partners, investors, pharmaceutical and biotechnology companies, medical institutions, research organizations and investment funds in both countries. BIOT may also facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing and commercialization. Any definitive transaction remains subject to separate negotiations, due diligence and definitive agreements.
The news matters because it marks a significant expansion of BIOT’s business development activities into clinical-stage oncology, a field with substantial unmet medical need. “We believe IN01 is a promising clinical-stage program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the patients who need it,” said Tomoki Nagano, Chief Executive Officer of BIOT. “Japan and China have the world’s largest lung cancer patient populations alongside world-class clinical research capabilities, placing them at the center of unmet medical needs in oncology. We share with CelSiege a mission to bring this technology to patients. As CelSiege’s authorized representative in these two markets, BIOT will work with a strong sense of ownership to identify partners and pursue collaborations that can advance the development and commercialization of IN01. Our enduring aspiration is to bring more smiles to patients and their families.”
According to information provided by CelSiege, IN01 is an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor (EGF). It is designed to stimulate the patient’s immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer cells. Development materials identify squamous non-small cell lung cancer (sqNSCLC) as the lead indication, with potential expansion into colorectal, head-and-neck and other cancers. IN01 is a clinical-stage asset and has not received marketing approval.
The medical need is stark. According to the International Agency for Research on Cancer, lung cancer was the world’s most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases, and the leading cause of cancer death, with approximately 1.8 million deaths. Non-small cell lung cancer accounts for approximately 80% to 85% of lung cancer cases, according to the American Cancer Society. Fortune Business Insights estimates the global NSCLC therapeutics market at approximately $38.49 billion in 2025. This third-party estimate relates to a broad therapeutic category and should not be read as an estimate of the addressable market, commercial potential or probability of success of IN01.
CelSiege Biosciences is a biotechnology company headquartered in Marseille, France, with operations in the United States, focused on the research and development of active immunotherapies. Its proprietary B-cell-mediated platform is designed to stimulate polyclonal antibody responses against disease-associated ligands, with applications in oncology and other therapeutic areas. For more information, visit CelSiege Biosciences.
BIOT is a diversified healthcare and biotechnology company focused on developing and expanding businesses across beauty, wellness, regenerative medicine and related healthcare sectors. Through its operations and strategic partnerships, BIOT seeks to build an integrated platform connecting innovative healthcare technologies, products and services with growth opportunities across Asia and other international markets. For more information, please visit https://instinct-biot.com/.<!–This announcement was originally distributed by NEWMEDIAWIRE.
